STOCK TITAN

Celanese Announces Polyamide and Polyester Price Increases in Asia

Celanese attributes the price adjustments to ongoing cost increases and evolving market conditions.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

DALLAS--(BUSINESS WIRE)-- Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, today announced a price increase for select polyamide and polyester products sold in Asia. This adjustment reflects ongoing cost increases and evolving market conditions, enabling Celanese to maintain reliable supply, consistent product quality and high levels of customer service.

The price increases noted below will be effective on all shipments on or after November 9, 2026, or as contracts otherwise allow. Additionally, individual grades may be subject to higher increase than specified below.

 

Base Resin

 

Brand / Material Type

Price Increase

Asia ($/kg)

PA 6, 66

 

Zytel®, Frianyl®, Celanyl®, Minlon®, CoolPoly® and Ecomid® PA6

$0.30

Zytel®, Frianyl®, Celanyl®, Minlon®, CoolPoly® and Ecomid® PA66

$0.20

PBT, PET

Crastin® PBT, Celanex ®PBT

$0.30

Rynite® PET

$0.30

About Celanese

Celanese is a global leader in chemistry, producing specialty material solutions used across most major industries and consumer applications. Our businesses use our chemistry, technology and commercial expertise to create value for our customers, employees and shareholders. We support sustainability by responsibly managing the materials we create and growing our portfolio of sustainable products to meet customer and societal demand. We strive to make a positive impact in our communities and to foster inclusivity across our teams. Celanese Corporation is a Fortune 500 company that employs more than 11,000 employees worldwide with 2025 net sales of $9.5 billion.

Forward-Looking Statements

This release may contain “forward-looking statements,” which include information concerning the company’s plans, objectives, goals, strategies, future revenues or performance, capital expenditures, financing needs, planned or announced price increases and their timing, and other information that is not historical information. When used in this release, the words “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” “will,” “effective,” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained in this release. Numerous factors, many of which are beyond the company’s control, could cause actual results to differ materially from those expressed as forward-looking statements. These factors include those that are discussed in the company’s filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

All registered trademarks are owned by Celanese International Corporation or its affiliates.

Celanese Contacts:
Investor Relations
Bill Cunningham
+1 972 443 4730
william.cunningham@celanese.com

Media Relations – Global
Jamaison Schuler
+1 972 443 4400
media@celanese.com

Media Relations Europe (Germany)
Petra Czugler
+49 69 45009 1206
petra.czugler@celanese.com

Media relations - Asia
Maria Xia
+86 21 3861 9368
maria.xia@celanese.com

Source: Celanese Corporation

Key Terms

polyamide technical
Polyamide is a class of plastics and fibers—think of it as long chains of repeating chemical links (like a beaded necklace)—that includes well-known materials such as nylon and other engineered nylons used in clothing, automotive parts, electronics, and industrial components. It matters to investors because polyamides are a basic industrial input: changes in their cost, availability, regulation or recyclability can affect manufacturers’ margins, product performance and supply chains, making them a driver of earnings and capital spending in many sectors.
polyester technical
A synthetic polymer used to make fibers and plastics, polyester is the kind of durable, wrinkle‑resistant “plastic fabric” found in clothing, home textiles and many packaging materials like drink bottles. Investors care because polyester’s cost, availability and recyclability affect the margins and production schedules of textile makers, packaging companies and chemical producers—so changes in oil prices, trade flows or recycling rules can ripple through revenues and profits.
pbt technical
Profit before tax (PBT) is a company’s earnings after all operating costs and interest are paid but before income taxes are subtracted. Think of it as the size of the paycheck before the tax withholdings are taken out; it shows how much the business generated from its operations and financing decisions alone. Investors use PBT to compare underlying profitability across companies and periods without tax differences masking performance.
pet technical
Positron emission tomography (PET) is a medical imaging test that creates a live map of how organs and tissues are working by tracking a tiny, safe amount of radioactive tracer inside the body. For investors, PET matters because it’s often used in clinical trials and diagnosis to show whether a drug or treatment is affecting disease — think of it as a performance meter that can speed regulatory decisions, change market forecasts, and affect a product’s commercial value.

Keep reading